Search

Your search keyword '"Vizkelety, Tamas"' showing total 13 results
Start Over Author "Vizkelety, Tamas" Publication Year Range Last 50 years
13 results on '"Vizkelety, Tamas"'

1. Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial

Author

Kater, Arnon P, Arslan, Önder, Demirkan, Fatih, Herishanu, Yair, Ferhanoglu, Burhan, Diaz, Marcos Gonzalez, Leber, Brian, Montillo, Marco, Panayiotidis, Panayiotis, Rossi, Davide, Skarbnik, Alan, Tempescul, Adrian, Turgut, Mehmet, Mellink, Clemens H, van der Kevie-Kersemaekers, Anne-Marie F, Lanham, Stuart, Sale, Ben, Del Rio, Luis, Popovic, Relja, Chyla, Brenda J, Busman, Todd, Komlosi, Viktor, Wang, Xifeng, Sail, Kavita, Pena, German E, Vizkelety, Tamas, and Forconi, Francesco

Published
2024
Full Text
View/download PDF

2. Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial

Author

Genetica Sectie Genoomdiagnostiek, Kater, Arnon P., Arslan, Önder, Demirkan, Fatih, Herishanu, Yair, Ferhanoglu, Burhan, Diaz, Marcos Gonzalez, Leber, Brian, Montillo, Marco, Panayiotidis, Panayiotis, Rossi, Davide, Skarbnik, Alan, Tempescul, Adrian, Turgut, Mehmet, Mellink, Clemens H., van der Kevie-Kersemaekers, Anne Marie F., Lanham, Stuart, Sale, Ben, Del Rio, Luis, Popovic, Relja, Chyla, Brenda J., Busman, Todd, Komlosi, Viktor, Wang, Xifeng, Sail, Kavita, Pena, German E., Vizkelety, Tamas, Forconi, Francesco, Genetica Sectie Genoomdiagnostiek, Kater, Arnon P., Arslan, Önder, Demirkan, Fatih, Herishanu, Yair, Ferhanoglu, Burhan, Diaz, Marcos Gonzalez, Leber, Brian, Montillo, Marco, Panayiotidis, Panayiotis, Rossi, Davide, Skarbnik, Alan, Tempescul, Adrian, Turgut, Mehmet, Mellink, Clemens H., van der Kevie-Kersemaekers, Anne Marie F., Lanham, Stuart, Sale, Ben, Del Rio, Luis, Popovic, Relja, Chyla, Brenda J., Busman, Todd, Komlosi, Viktor, Wang, Xifeng, Sail, Kavita, Pena, German E., Vizkelety, Tamas, and Forconi, Francesco

Published
2024

3. Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study

Author

Herling, Marco, primary, Dearden, Claire, additional, Zaja, Francesco, additional, El-Sharkawi, Dima, additional, Ding, Wei, additional, Bellido, Mar, additional, Khot, Amit, additional, Tick, Lidwine, additional, Jacobsen, Eric, additional, Eyre, Toby A., additional, Roos-Weil, Damien, additional, Kadia, Tapan, additional, Lucchini, Elisa, additional, Pflug, Natali, additional, Davids, Matthew S., additional, Pena, German, additional, Mukherjee, Nabanita, additional, Badawi, Mohamed, additional, Vizkelety, Tamas, additional, and Staber, Philipp B., additional

Published
2024
Full Text
View/download PDF

4. Debulking before Initiation of Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Results from a Phase 3b Study

Author

Flinn, Ian W., primary, Andorsky, David, additional, Melear, Jason, additional, Manda, Sudhir, additional, Anz, Bertrand, additional, Kolibaba, Kathryn, additional, Yimer, Habte, additional, Burke, John M., additional, Fanning, Suzanne, additional, Courtright, Jay, additional, Islas-Ohlmayer, Miguel, additional, Kambhampati, Suman, additional, Vizkelety, Tamas, additional, Pesko, John, additional, Chyla, Brenda, additional, Jiang, Dingfeng, additional, and Sharman, Jeff P., additional

Published
2021
Full Text
View/download PDF

5. Real-world treatment patterns and health care resource use for patients with myelofibrosis: results from the METER study

Author

Gupta, Vikas, Tomuleasa, Ciprian, Barranco Lampon, Gilberto Israel, Hou, Hsin-An, Helbig, Grzegorz, Vachhani, Pankit, Symeonidis, Argiris, Haznedaroglu, Ibrahim, Galvez, Kenny, Tatsch, Fernando, Chopra, Avijeet S., Zhang, Meng, Vizkelety, Tamas, Murray, Bryan, and Ross, David M.

Abstract

•In the JAK inhibitor era, RUX is the most used therapy as 1L, 2L, or subsequent lines of therapy for MF.•In patients ≤70 years, the use of transplant as 1L therapy is uncommon with a cumulative incidence increasing from 2.2% at week 24 to 11.0% at week 156.

Published
2025
Full Text
View/download PDF

9. Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Interim Results from a Phase 3b Study

Author

Flinn, Ian W., primary, Andorsky, David, additional, Melear, Jason M., additional, Manda, Sudhir, additional, Anz, Bertrand M., additional, Kolibaba, Kathryn, additional, Yimer, Habte A., additional, Burke, John M., additional, Fanning, Suzanne R., additional, Courtright, Jay, additional, Islas-Ohlmayer, Miguel, additional, Kambhampati, Suman, additional, Jiang, Daniel Dingfeng, additional, Pesko, John C., additional, Vizkelety, Tamas, additional, Sharmokh, Simon, additional, and Sharman, Jeff P, additional

Published
2020
Full Text
View/download PDF

10. CLL-076: Phase 3b Study to Evaluate Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia

Author

Sharman, Jeff, primary, Andorsky, David, additional, Melear, Jason, additional, Manda, Sudhir, additional, III, Bertrand Anz, additional, Yimer, Kathryn Kolibaba Habte, additional, Burke, John, additional, Fanning, Suzanne, additional, Courtright, Jay, additional, Islas-Ohlmayer, Miguel, additional, Kambhampati, Suman, additional, Jiang, Dingfeng, additional, Pesko, John, additional, Vizkelety, Tamas, additional, Sharmokh, Simon, additional, Nielsen, Jacqueline, additional, and Flinn, Ian, additional

Published
2020
Full Text
View/download PDF

11. Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study

Author

Sharman, Jeff P., primary, Andorsky, David, additional, Melear, Jason M., additional, Manda, Sudhir, additional, Anz, Bertrand M., additional, Kolibaba, Kathryn S., additional, Yimer, Habte A, additional, Burke, John M, additional, Fanning, Suzanne R., additional, Courtright, Jay, additional, Islas-Ohlmayer, Miguel, additional, Kambhampati, Suman, additional, Masud, Abdullah Al, additional, Zimmerman, Todd, additional, Nielsen, Jacqueline, additional, Vizkelety, Tamas, additional, Jiang, Dingfeng, additional, and Flinn, Ian W., additional

Published
2019
Full Text
View/download PDF

13. Real-World Treatment Patterns and Healthcare Resource Use for Patients with Myelofibrosis: Results from the METER Study.

Author

Gupta V, Tomuleasa C, Barranco G, Hou HA, Helbig G, Vachhani P, Symeonidis A, Haznedaroglu IC, Galvez K, Tatsch F, Chopra AS, Zhang M, Vizkelety T, Murray BC, and Ross DM

Abstract

Myelofibrosis (MF) is a myeloproliferative neoplasm that was most commonly treated with hydroxyurea (HU) prior to approval of ruxolitinib (RUX), now the standard of care. Factors that influence changes in MF treatment in real-world settings are not well understood. The METER study (NCT05444972) was a multi-country retrospective chart review of MF treatment patterns, treatment effectiveness, and healthcare resource utilization. Of 997 eligible patients, 65.9% had primary MF, and 11.7% were transfusion-dependent. The median (IQR) time from MF diagnosis to start of initial treatment (index date) was 29 (1-140) days. RUX was the most common first-line (1L) therapy (49.0%), followed by hydroxyurea (40.2%); 48.5% of patients remained on 1L therapy through Week 156. A total of 77 patients underwent allogeneic stem cell transplantation; use of transplantation was uncommon as 1L therapy and increased from 2.2% at Week 24 to 11.0% at Week 156 in patients 70 years of age. Median (95% CI) overall survival was 79.1 (70.8-non-estimable [NE]) months in all patients, 142.3 (74.1-NE) months for non-RUX patients, 77.6 (64.2-85.9) months for RUX 1L patients, and 72.6 (62.0-NE) months for RUX 2L+ patients. Of patients who experienced ≥1 corresponding event during the observational period, the median (IQR) hospital length of stay (LoS) (n=520), intensive care unit LoS (n=71), and number of transfusion events (n=375) were 16 (7-37) days, 5 (2-13) days, and 12 (4-26), respectively. Despite improvements, there was a high degree of hospitalization and transfusion events among these patients in routine practice. NCT05444972., (Copyright © 2024 American Society of Hematology.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results